Skip to main content

Maple Syrup Urine Disease

Gene therapy developed for maple syrup urine disease shows promise


A study led by UMass Chan Medical School researchers has demonstrated that a gene therapy to correct a mutation that causes maple syrup urine disease (MSUD) prevented newborn death, normalized growth, restored coordinated expression of the affected genes and stabilized biomarkers in a calf as well as in mice.

"Simply put, we believe the gene therapy demonstrated in both animal species, especially in the cow, very well showcases the therapeutic potential for MSUD, in part because the diseased cow, without treatment, has a very similar metabolic profile as the patients," said Dan Wang, Ph.D., assistant professor of genetic & cellular medicine.

Dr. Wang is co-principal investigator with Heather Gray-Edwards, DVM, Ph.D., assistant professor of genetic & cellular medicine; Guangping Gao, Ph.D., the Penelope Booth Rockwell Chair in Biomedical Research, director of the Horae Gene Therapy Center, director of the Li Weibo Institute for Rare Diseases Research and chair and professor of genetic & cellular medicine; and Kevin Strauss, MD, adjunct professor of pediatrics and head of therapeutic development at the Clinic for Special Children in Gordonville, Pennsylvania.

The study is published in Science Translational Medicine.

MSUD is a rare genetic inborn error of metabolism characterized by recurrent life-threatening neurologic crises and progressive brain injury that can only be managed with an exacting prescription diet or liver transplant from a donor.

The condition occurs in one in 197,714 live births but is much more common in certain regions of Brazil, Portugal, Turkey, the Philippines, and among people of Ashkenazi or Mennonite descent. Among the Mennonite population, such as communities in Lancaster County, Pennsylvania, the incidence of MSUD is one in 400.

MSUD is caused when a mutated form of the BCKDHA, BCKDHB or DBT gene is inherited from both parents. As a result of this mutation, the body is unable to break down certain parts of proteins. This leads to the build-up of toxic substances that can cause organ and brain damage.

Researchers in the current study designed a dual-function recombinant adeno-associated virus serotype 9 vector to deliver a gene replacement to the liver, muscle, heart and brain. They wrote that the one-time treatment holds promise as a therapeutic alternative to prescription diet and liver transplant for the treatment of MSUD types 1A and 1B, the two most common forms of MSUD in humans.

Data from the calf translated more directly to humans for the purposes of understanding pharmacokinetics, specific treatment effects on muscle and brain tissue, and long-term durability through an extended phase of growth.

"We believed gene therapy could be a breakthrough for patients with MSUD, and in August 2018, we met on a cattle farm in Iowa to pursue that vision: to develop and test gene therapy in a unique animal model, a newborn calf with MSUD," said Dr. Strauss.

"In the years that followed, physicians at the Clinic for Special Children worked intently with scientists and veterinarians from UMass Chan Medical School to achieve that goal, drawing their inspiration from the hopes and struggles of the MSUD community. For people worldwide living with MSUD, this signifies major progress on the path to a brighter future."

Wang said that researchers are exploring the next steps to translate this gene therapy into clinical use as a Phase I/II study with the U.S. Food and Drug Administration.

branched-chain amino acids, leucine, isoleucine, valine, metabolic disorder, MSUD, maple syrup odor, amino acid metabolism, BCKD complex, genetic mutation, autosomal recessive, metabolic crisis, ketoacidosis, neurotoxicity, dietary management, newborn screening, metabolic genetics, enzyme deficiency, dietary restriction, liver transplantation, gene therapy

#MapleSyrupUrineDisease #MSUD #MetabolicDisorder #GeneticMutation #BranchedChainAminoAcids #AminoAcidMetabolism #BCKD #NewbornScreening #MetabolicCrisis #Ketoacidosis #Neurotoxicity #EnzymeDeficiency #DietaryManagement #LiverTransplant #GeneTherapy #MetabolicGenetics #RareDisease #InheritedDisorder #PediatricNeurology #MedicalGenetics

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...
Post a Comment
Read more